Yüklüyor......
Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials
Non-alcoholic steatohepatitis (NASH) results from inflammation and hepatocyte injury in the setting of hepatic steatosis. Non-alcoholic steatohepatitis increases the risk of progression to liver fibrosis and cirrhosis, and is the most rapidly growing etiology for liver failure and indication for liv...
Kaydedildi:
| Yayımlandı: | J Clin Transl Hepatol |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
XIA & HE Publishing Inc.
2018
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6160309/ https://ncbi.nlm.nih.gov/pubmed/30271738 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14218/JCTH.2017.00056 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|